Scientists at the University of Copenhagen discover a link between birthweight and the risk of health complications from obesity during childhood. The findings highlight the need for prevention and treatment approaches for children with obesity who were born with a lower birth weight.
Scientists at the University of Copenhagen discover a link between birthweight and the risk of health complications from obesity during childhood. The findings highlight the need for prevention and treatment approaches for children with obesity who were born with a lower birth weight.
Hundreds of millions of people live with obesity, which is normally measured as a higher-than-optimal body mass index (BMI). While an elevated BMI increases the risk of a range of cardiometabolic diseases and is responsible for around five million deaths a year according to the World Health Organization, not everyone is equally at risk.
Scientists at the University of Copenhagen have now discovered that children born with a low birth weight are especially at risk of health complications if they later develop obesity.
“Our study shows that the link between low birth weight and cardiometabolic disease risk can be detected already in childhood – and that this is the case for both the actual birth weight and the genetic determinants of birth weight,” says Sara Stinson, Postdoctoral research fellow, and first author of the study.
“It also supports the theory that individuals who were born low birth weight, or who are genetically predisposed to low birth weight, may be more vulnerable to health hazards – such as excess visceral fat – throughout the course of life.”
Interrogating the link between disease risk and birth weight
Scientists have already discovered that people born with a high birth weight are more at risk of developing a higher-than-optimal BMI later in life. On the other hand, there is strong evidence that people born with a low birth weight, or have a genetic predisposition to low birth weight, have an increased risk of cardiometabolic diseases like type 2 diabetes.
What is less well understood is how and when in life people with these risk factors actually develop cardiometabolic disease. It is also unclear how overweight and obesity plays a role in the development of cardiometabolic disease, depending on birth weight.
To learn more, the team of scientists analysed a Danish cohort called The HOLBÆK Study of more than 4,000 children and adolescents with and without obesity. The cohort contains a wide variety of health-related data including birth weight, BMI, clinical evaluations, blood samples, biomarkers, and a polygenic score for birth weight – a calculation that combines the effect of many genetic variants related to birth weight.
Underdeveloped subcutaneous fat increases disease risk
The scientists reported the results of their analysis in the journal eBiomedicine. They showed that developing obesity as a child presents more health risks if the child is born underweight. One example is sensitivity to the hormone insulin, which helps to regulate blood sugar levels. Low insulin sensitivity is a risk factor for type 2 diabetes.
“If we look at measures of insulin sensitivity, we see that being born with a low birth weight does not have an adverse effect in children with normal weight. However, in children with obesity, we see near normal insulin sensitivity in children born with a high birth weight and drastically decreased insulin sensitivity in children with low birth weight,” says PhD Student Pauline Kromann Reim, from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and second author of the study.
The reason could be, literally, skin deep. The body normally stores fat in fat cells beneath the skin, called subcutaneous fat. But these fat stores are may be underdeveloped in children who are born underweight, and they can therefore not expand as needed to store more fat.
Instead, their body stores fat, called visceral fat, around their organs. While subcutaneous fat is not dangerous for the body – but is essential for its proper functioning – higher levels of visceral fat have a range of negative health impacts including an increased risk of type 2 diabetes.
The scientists also found a link between low birth weight and increased levels of fat in the liver, which decreases insulin sensitivity and could explain why low birth weight individuals are – already in childhood – at a higher risk of developing type 2 diabetes. Blood samples from people with low birth weight also had higher levels of obesity-related biomarkers in their blood.
Low birth weight children need tailored prevention and treatment
Based on the findings, Clinical Associate Professor Jens Christian Holm from The Children’s Obesity Clinic, Copenhagen University Hospital Holbæk, and co-senior author on the paper, calls for prevention and treatment approaches that are tailored specifically for children with obesity who were born with a lower birth weight.
“Such targeted strategies could potentially reduce their risk of developing obesity-related cardiometabolic complications,” says Jens Christian Holm.
“Early intervention and more precision in who to treat and who not to treat are key elements in the battle of cardiometabolic disease”, adds Professor Torben Hansen from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, and co-senior author on the paper.
Journal
EBioMedicine
Article Title
The interplay between birth weight and obesity in determining childhood and adolescent cardiometabolic risk
Article Publication Date
24-Jun-2024
COI Statement
C.E.F. has received speaker honoria from The Danish Society for General Practice, Novo Nordisk, Nestlé and payment for manuscript writing from The Danish Health Authority. C.B. and T.H. have stocks in Novo Nordisk. A.K. receives royalties from Gyldendal, payment for lectures from Norgine, Siemens, Nordic Bioscience, Novo Nordisk. A.K. has two patents planned/pending, participates on an advisory board for Norgine, Siemens, Novo Nordisk, B&I. A.K. has a leadership role as the Secretary General European Association for the Study of The Liver (EASL) 2023–2025. A.K. has received equipment, materials, and drugs from Norgine (Rifaximin), Siemens (ELF Test), Echosence (FibroScan), and Nordic Bioscience (ECM markers). A.K. has finical interest as the Board member and co-founder Evido. J-C.H. has received payment for expert testimony from Novo Nordisk and support for meetings and travel from Rhytm, provides training and treatment of obesity. The authors declare no other competing interests from remaining coauthors.
Discover more from Science
Subscribe to get the latest posts sent to your email.